Live Breaking News & Updates on Zelnecirnon

Stay informed with the latest breaking news from Zelnecirnon on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Zelnecirnon and stay connected to the pulse of your community

Rapt slapped with phase II hold on CCR4 prospect

On the verge of top-line data from its phase IIb trial with oral small-molecule CC chemokine receptor 4 (CCR4) antagonist zelnecirnon in atopic dermatitis (AD), due around the middle of this year, Rapt Therapeutics Inc. said the U.S. FDA has imposed a clinical hold on that study with the otherwise promising drug, also known as RPT-193, in AD as well as the phase IIa trial with the same compound in asthma.

Rapt-therapeutics-inc , Rapt-therapeutics , Rapt-therapeutics-inc- , Zelnecirnon , Rpt-193 , Atopic-dermatitis , Asthma , Clinical-hold , Bioworld , Clinical , Respiratory